brimonidine gel rosacea Mirvaso
Selected indexed studies
- Symptomatic bradycardia associated with topical brimonidine gel (Mirvaso) administration: a case report. (Eur Heart J Case Rep, 2024) [PMID:39045525]
- Brimonidine. (, 2006) [PMID:30000738]
- Brimonidine gel (Mirvaso) for rosacea. (Med Lett Drugs Ther, 2013) [PMID:24129112]
_Worker-drafted node — pending editorial review._
Connections
brimonidine gel rosacea Mirvaso is a side effect of
Sources
- Topical brimonidine for the management of facial erythema in rosacea: a histological, histometric, and immunohistochemical study. (2023) pubmed
- Dermatological Adverse Events Associated with Topical Brimonidine Gel 0.33% in Subjects with Erythema of Rosacea: A Retrospective Review of Clinical Studies. (2015) pubmed
- Emerging Medical Therapies in Rosacea: A Narrative Review. (2023) pubmed
- Brimonidine. (2006) pubmed
- Symptomatic bradycardia associated with topical brimonidine gel (Mirvaso) administration: a case report. (2024) pubmed
- Brimonidine gel (Mirvaso) for rosacea. (2013) pubmed
- Brimonidine for erythema caused by rosacea. (2014) pubmed
- Inhibition of mast cell infiltration in an LL-37-induced rosacea mouse model using topical brimonidine tartrate 0.33% gel. (2017) pubmed
- Brimonidine gel 0.33% rapidly improves patient-reported outcomes by controlling facial erythema of rosacea: a randomized, double-blind, vehicle-controlled study. (2015) pubmed
- Rosacea or photodamaged skin? Use of brimonidine gel in differentiating erythema in the two conditions. (2017) pubmed